Review article: Similarities and differences among delayed-release proton-pump inhibitor formulations

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 22, Issue 3, 2005, Pages 20-24

  Horn, J R ^a   Howden, C W ^b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Division of Gastroenterology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; STOMACH SECRETION INHIBITOR;

AREA UNDER THE CURVE; CHRONIC DRUG ADMINISTRATION; DELAYED DRUG RELEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; ENTERIC COATED TABLET; GASTROESOPHAGEAL REFLUX; HUMAN; IMMEDIATE RELEASE FORMULATION; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; STOMACH ULCER;

EID: 28944450056     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02714.x     Document Type: Review

References (20)

1. Freston JW, Chiu YL, Mulford DJ, Ballard ED. Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. Aliment Pharmacol Ther 2003; 17: 361-7.
2. Sharma VK, Heinzelmann EJ, Steinberg EN, Vasudeva R, Howden CW. Nonencapsulated, intact omeprazole granules effectively suppress intragastric acidity when administered via a gastrostomy. Am J Gastroenterol 1997; 92: 848-51.
3. Sharma VK, Vasudeva R, Howden CW. The effects on intragastric acidity of per-gastrostomy administration of an alkaline suspension of omeprazole. Aliment Pharmacol Ther 1999; 13: 1091-5.
4. Sharma VK, Ugheoke EA, Vasudeva R, Howden CW. The pharmacodynamics of lansoprazole administered via gastrostomy as intact, non-encapsulated granules. Aliment Pharmacol Ther 1998; 12: 1171-4.
5. Sharma VK, Vasudeva R, Howden CW. Simplified lansoprazole suspension - a liquid formulation of lansoprazole - effectively suppresses intragastric acidity when administered through a gastrostomy. Am J Gastroenterol 1999; 94: 1813-7.
6. Sharma VK, Peyton B, Spears T, Raufman JP, Howden CW. Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate. Aliment Pharmacol Ther 2000; 14: 887-92.
7. Song JC, Quercia RA, Fan C, Tsikouris J, White CM. Pharmacokinetic comparison of omeprazole capsules and a simplified omeprazole suspension. Am J Health Syst Pharm 2001; 58: 689-94.
8. Jones DB, Howden CW, Burget DW, Kerr GD, Hunt RH. Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs. Gut 1987; 28: 1120-7.
9. Howden CW, Jones DB, Peace KE, Burget DW, Hunt RH. The treatment of gastric ulcer with antisecretory drugs. Relationship of pharmacological effect to healing rates. Dig Dis Sci 1988; 33: 619-24.
10. Howden CW, Hunt RH. The relationship between suppression of acidity and gastric ulcer healing rates. Aliment Pharmacol Ther 1990; 4: 25-33.
11. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastrooesophageal reflux disease. Digestion 1992; 51 (Suppl. 1): 59-67.
12. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003; 17: 1507-14.
13. Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 2616-20.
14. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656-65.
15. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575-83.
16. Labenz J, Armstrong D, Lauritsen K, et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO Study. Aliment Pharmacol Ther 2005; 21: 739-46.
17. Howden C, Ballard E, Robieson W. Evidence for therapeutic equivalence of lansoprazole 30 mg and esomeprazole 40 mg in the treatment of erosive oesophagitis. Clin Drug Investig 2002; 22: 99-109.
18. Chey W, Huang B, Jackson R. Lansoprazole and esomeprazole in symptomatic GERD. A double-blind, randomised, multicentre trial in 3000 patients confirms comparable symptom relief. Clin Drug Investig 2003; 23: 69-84.
19. McQuaid KR, Laine L. Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials. Clin Gastroenterol Hepatol 2005; 3: 553-63.
20. Hepburn B, Goldlust B. Comparative effects of an omeprazole antacid complex-immediate release (OACIR) and omeprazole delayed-release (OME-DR) on omeprazole pharmacokinetics and gastric pH in healthy subjects. Gastroenterology 2003; 124: A228 (Abstract).